Cite
HARVARD Citation
Donohue, J. et al. (2019). Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary pharmacology & therapeutics. p. . [Online].